SkinDermic®  develops novel, safer and highly effective first-in-class drug candidates, internally discovered, for the treatment of acne, Kaposi’s Sarcoma and other HHV8 associated diseases up to Phase-1/2 (proof of concept) clinical trials in human.

In parallel, SkinDermic® also develops, using its own advanced research programs, biotechnology-derived first-in-class ingredients for use as cosmetics.